Announcement of FY26 Results

Key points

• FY26 total revenue of $7.7 million, up 3% on the previous corresponding period
• Marketplace recurring revenue up 73% and Analytics revenue up 25% on FY25
• Transformational Strategic Alliance with Sigma Healthcare Limited executed
• Gross Margin increased to 84% (FY25: 82%)
• Closing cash position of $2.6 million

Full summary

Pharmx Technologies Ltd announced its FY26 results, highlighting a 3% increase in total revenue to $7.7 million. The Marketplace saw a significant boost, with recurring revenue up 73% and analytics revenue up 25% compared to FY25. The company also formed a strategic alliance with Sigma Healthcare Limited, with Sigma holding 10% of Pharmx and gaining a seat on the Pharmx Board. Gross margin increased to 84% from 82% in FY25. The company ended the year with a closing cash position of $2.6 million.

Guidance

FY26 total revenue of $7.7 million, up 3% on the previous corresponding period

Outlook

Pharmx plans to scale Marketplace volumes, expand supplier growth, maximize Sigma alliance opportunities, and enhance data and analytics capabilities in FY27.